XML 60 R49.htm IDEA: XBRL DOCUMENT v3.26.1
SEGMENT REPORTING - Schedule of Segment Revenue and Significant Segment Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
REVENUE:            
Total segment revenue $ 0   $ 18,168   $ 367 $ 229,414
LESS:            
Research and development (22,331)   (43,503)   (38,428) (92,212)
Other external costs (5,377)   (8,542)   (11,576) (17,405)
Net income (loss) (28,710) $ (23,708) (30,696) $ 148,451 (52,418) 117,755
Reportable Segment            
REVENUE:            
Total segment revenue 0   18,168   367 229,414
LESS:            
Compensation costs (excluding stock based compensation) (7,725)   (13,842)   (15,915) (27,619)
Other segment items (3,618)   (178)   (8,121) (13,336)
Net income (loss) (28,710)   (30,696)   (52,418) 117,755
Reportable Segment | Rinvatercept program expenses            
LESS:            
Research and development (4,101)   (1,431)   (6,751) (2,948)
Reportable Segment | Elritercept program expenses            
LESS:            
Research and development (14)   (15,636)   (17) (34,531)
Reportable Segment | Cibotercept program expenses            
LESS:            
Research and development (267)   (4,059)   57 (9,967)
Reportable Segment | Preclinical & development expenses            
LESS:            
Research and development (6,111)   (1,981)   (8,117) (3,725)
Reportable Segment | Other external costs            
LESS:            
Other external costs $ (6,874)   $ (11,737)   $ (13,921) $ (19,533)